Comparison of serum hepatitis C virus (HCV) RNA and core antigen levels in patients coinfected with human immunodeficiency virus and HCV and treated with interferon plus ribavirin

Journal of Clinical Microbiology

Volumn 44, Issue 2, 2006, Pages 417-422

  Pivert, A ^a   Payan, C ^a   Morand, P ^b   Fafi Kremer, S ^b   Deshayes, J ^c   Carrat, F ^c   Pol, S ^d   Cacoub, P ^e   Perronne, C ^f   Lunel, F ^a  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b GRENOBLE UNIVERSITY HOSPITAL   (France)

^c INSERM   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f RAYMOND POINCARÉ HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2C INTERFERON; HEPATITIS C ANTIGEN; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DEVELOPING COUNTRY; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VIRUS IDENTIFICATION;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIGENS; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2B; REAGENT KITS, DIAGNOSTIC; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRAL CORE PROTEINS;

HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 32344441519     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.44.2.417-422.2006     Document Type: Article

References (26)

1. Agence Nationale d'Accreditation et d'Evalution en Sante. 2002. Consensus conference: treatment of hepatitis C. Gastroenterol. Clin. Biol. 26:B303-B320.
2. Berg, T., C. Sarrazin, E. Herrman, H. Hinrichsen, T. Gerlach, R. Zachoval, B. Wiedenmann, U. Hopf, and S. Zeuzem. 2003. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 37:600-609.
3. Carrat, F., F. Bani-Sadr, S. Pol, E. Rosenthal, F. Lunel-Fabiani, A. Benzekri, P. Morand, C. Goujard, G. Pialoux, L. Piroth, D. Salmon-Ceron, C. Degott, P. Cacoub, C. Perronne, et al. 2004. Pegylated interferon alfa-2b versus standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 292:2839-2848.
4. Chung, R., J. Andersen, P. Volberding, G. Robbins, T. Liu, K. Sherman, M. Peters, M. Koziel, A. Bahn, B. Alston, D. Colquhoun, T. Nevin, G. Harb, and C. Van der Host. 2004. Pegylated interferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV co-infected persons. N. Engl. J. Med. 351:451-459.
5. Davis, G. L., J. B. Wong, J. G. McHutchison, M. P. Manns, J. Harvey, and J. Albrecht. 2003. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 38:645-652.
6. Fried, M., M. Shiffman, R. Reddy, C. Smith, G. Marinos, F. Gonçales, D. Häussinger, M. Diago, G. Carosi, D. Dhumeaux, A. Craxi, A. Lin, J. Hoffman, and J. Yu. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347:975-982.
7. Gaudy, C., C. Thevenas, J. Tichet, N. Mariotte, A. Goudeau, and F. Dubois. 2005. Usefulness of the hepatitis C virus core antigen assay for screening of a population undergoing routine medical checkup. J. Clin. Microbiol. 43:1722-1726.
8. Hayashi, K., S. Hasuike, K. Kusumoto, A. Ido, H. Uto, N. Kenji, M. Kohara, S. O. Stuver, and H. Tsubouchi. 2005. Usefulness of a new immuno-radiometric assay to detect hepatitis C core antigen in a community-based population. J. Viral Hepat. 12:106-110.
9. Laperche, S., N. Le Marrec, N. Simon, F. Bouchardeau, C. Defer, M. Maniez-Montreuil, T. Levayer, J. P. Zappitelli, and J. J. Lefrere. 2003. A new HCV core antigen assay based on disassociation of immune complexes: an alternative to molecular biology in the diagnosis of early HCV infection. Transfusion 43:958-962.
10. Lunel, F., P. Veillon, I. Fouchard-Hubert, V. Loustaud-Ratti, A. Abergel, C. Silvain, H. Rifflet, A. Blanchi, X. Causse, Y. Bacq, C. Payan, et al. 2003. Antiviral effect of ribavirin in early non-responders to interferon monotherapy assessed by kinetics of hepatitis C virus RNA and hepatitis C virus core antigen. J. Hepatol. 39:826-833.
11. Manns, M. P., J. McHutchison, S. C. Gordon, V. K. Rustgi, M. Shiffman, R. Reindollar, Z. Goodman, K. Koury, M. H. Ling, and J. Albrecht. 2001. Peginterferon α2b plus ribavirin compared with interferon α2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958-965.
12. Massaguer, A., X. Forns, J. Costa, A. Feliu, M. Garcia-Retortillo, M. Navasa, A. Rimola, J. C. Garcia-Valdecasas, and J. M. Sanchez-Tapias. 2005. Performance of HCV core antigen immunoassay in monitoring viral load after liver transplantation. Transplantation 79:1441-1444.
13. McHutchison, J., L. Blatt, A. Sedghi-Vaziri, J. Russell, P. Schmid, and A. Conrad. 1998. Is there an optimal time to measure quantitative HCV RNA to predict non response following interferon treatment for chronic HCV infection? J. Hepatol. 29:362-368.
14. National Institutes of Health. 2002. National Institutes of Health Consensus Development Conference statement. Management of hepatitis C: 2002-June 10-12, 2002. Hepatology 36:S3-S20.
15. Neumann, A., N. Lam, H. Dehari, D. Grecht, T. Wiley, T. Layden, and A. Perelson. 1998. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon alpha therapy. Science 282:103-107.
16. Poynard, T., P. Marcellin, S. Lee, C. Niederau, G. Minuk, G. Ideo, V. Bain, J. Heathcote, S. Zeuzem, C. Trepo, and J. Albrecht. 1998. Randomised trial of interferon a2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 352:1426-1432.
17. Poynard, T., J. McHutchison, Z. Goodman, M.-H. Ling, and J. Albrecht. 2000. Is an "à la carte" combination interferon α2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? Hepatology 31:211-218.
18. Schüttler, C. G., C. Thomas, T. Discher, G. Friese, J. Lohmeyer, R. Schuster, S. Schaefer, and W. H. Gerlich. 2004. Variable ratio of hepatitis C virus RNA to viral core antigen in patient sera. J. Clin. Microbiol. 42:1977-1981.
19. Seme, K., M. Poljak, D. Z. Babic, T. Mocilnik, and A. Vince. 2005. The role of core antigen detection in management of hepatitis C: a critical review. J. Clin. Virol. 32:92-101.
20. Soffredini, R., M. G. Rumi, M. L. Parravicini, G. Ronchi, E. Del Ninno, A. Russo, and M. Colombo. 2004. Serum levels of HCV core antigen as a marker of infection and response to therapy. Am. J. Gastroenterol. 99:1738-1743.
21. Takahashi, M., H. Saito, M. Higashimoto, K. Atsukawa, and H. Ishii. 2005. Benefit of hepatitis C virus core antigen assay in prediction of therapeutic response to interferon and ribavirin combination therapy. J. Clin. Microbiol. 43:186-191.
22. Tillmann, H. L., J. Wiegand, I. Glomb, A. Jelineck, G. Picchio, H. Wedemeyer, and M. P. Manns. 2005. Diagnostic algorithm for chronic HCV infection: role of the new HCV-core antigen assy. Z. Gastroenterol. 43:11-16.
23. Torriani, F. J., M. Rodriguez-Torres, J. Rockstroh, E. Lissen, J. Gonzalez-Garcia, A. Lazzarin, G. Carosi, J. Sasadeusz, C. Katlama, J. Montaner, H. Settel, S. Passe, J. De Phamphilis, F. Duff, U. M. Schrenk, and D. Dieterich. 2004. Peg-interferon alfa-2a plus ribavirin for chronic HCV infection in HIV-infected patients. N. Engl. J. Med. 351:438-450.
24. Veillon, P., C. Payan, G. Picchio, M. Maniez-Montreuil, P. Guntz, and F. Lunel. 2003. Comparative evaluation of the total hepatitis C virus core antigen, branched-DNA, and Amplicor Monitor assays in determining viremia for patients with chronic hepatitis C during interferon plus ribavirin combination therapy. J. Clin. Microbiol. 41:3212-3220.
25. Zanetti, A., L. Romano, M. Brunetto, M. Colombo, G. Bellati, and C. Tackney. 2003. Total HCV core antigen assay: a new marker of hepatitis C viremia for monitoring the progress of therapy. J. Med. Virol. 70:27-30.
26. Zeuzem, S., J. Schmidt, J. H. Lee, M. von Wagner, G. Teuber, and R. Roth. 1998. Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alpha on viral turnover. Hepatology 28:245-252.